Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01731470 · ClinicalTrials.gov registry record · NA
Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)
A NA study of Interstitial Cystitis and Pelvic Pain, sponsored by Kenneth Peters, MD.
- Completed
- Registry status
- NA
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT01731470: Completed NA study of Interstitial Cystitis and Pelvic Pain, sponsored by Kenneth Peters, MD.
NCT01731470 is a NA study of Interstitial Cystitis and Pelvic Pain that has completed, run by Kenneth Peters, MD. The registered enrollment target is 14 participants, below the 362-participant average among 26 other Interstitial Cystitis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01731470, a NA study of Interstitial Cystitis and Pelvic Pain, has completed, sponsored by Kenneth Peters, MD.
- COMPLETED
- Registry status
- NA
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
Interstitial cystitis/painful bladder syndrome (IC/PBS) is a poorly understood chronic disorder of unknown etiology consisting of irritative bladder symptoms and pelvic pain that dramatically affects quality of life. Preclinical study data (obtained by using an IC/PBS model in Sprague-Dawley female rats) have demonstrated normalization of urinary frequency indicating that LP may be a potent protectant of the bladder mucosa against inflammation and irritation. Intravesical LP has so far demonstrated an excellent safety profile and minimal toxicity at concentrations of 2 mg/ml. Thus, we hypothesize that intravesical instillation of LP may form a molecular film on bladder ulcer surfaces in patients with IC and provide a safe, effective, and minimally invasive treatment option to alleviating symptoms.
Primary Outcome
The O'Leary-Sant IC Symptom Index (ICS-I) total score ranges from 0 to 20 and the Problem Index (ICP-I) total score ranges from 0 to 16. Each index has 4 questions and lower scores represent a better outcome. A total ICSI/ICPI score is obtained by adding the total scores from both indices. The combined ICSI/ICPI total score ranges from 0 to 36.
Conditions Studied
Interventions
- BIOLOGICAL Liposomes
Study Locations (1)
Michigan
- William Beaumont Hospital - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-07 |
| Est. Completion | 2013-08 |
| Phase | NA |
What the finished NCT01731470 record still lists
NCT01731470 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 362-participant average among 26 other Interstitial Cystitis trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Interstitial Cystitis appearing as the primary indexed condition, and to 1 intervention - of which Liposomes is the first listed.
NCT01731470 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT01731470 about?
NCT01731470 is a clinical study titled "Intravesical Liposomes for Interstitial Cystitis/Painful Bladder Syndrome (IC/PBS)". Interstitial cystitis/painful bladder syndrome (IC/PBS) is a poorly understood chronic disorder of unknown etiology consisting of irritative bladder symptoms and pelvic pain that dramatically affects quality of life. Preclinical study data (obtained by using an IC/PBS model in Sprague-Dawley female...
What is the current status of trial NCT01731470?
This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2012-07. Estimated completion is 2013-08.
What conditions does trial NCT01731470 study?
This clinical trial studies the following conditions: Interstitial Cystitis, Pelvic Pain.
What interventions are being tested in trial NCT01731470?
The interventions under investigation include: Liposomes (BIOLOGICAL).
Who is sponsoring clinical trial NCT01731470?
This trial is sponsored by Kenneth Peters, MD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01731470 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Interstitial Cystitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01731470's enrollment target sits among peer trials
14 24th of 26 higher than 2 of 26 other Interstitial Cystitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Interstitial Cystitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment
RECRUITING · NA
-
Motor Cortical Neuromodulation in Women With Interstitial Cystitis/Bladder Pain Syndrome
RECRUITING · NA
-
EPPIC: Easing Pelvic Pain Interventions Clinical Research Program
RECRUITING · NA
-
Investigation of PEMF Therapy for Female Patients With IC/BPS
RECRUITING · NA
-
Acupuncture First for IC/BPS
RECRUITING · NA
-
Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia